Bert Slonim concentrates on complex commercial litigation, particularly multi-district pharmaceutical product liability cases. He has represented manufacturers of prescription drugs (including hormone replacement therapy, erectile dysfunction, diabetes, antibiotic, and anti-psychotic medications), implanted medical devices, agricultural chemicals, electrical equipment, aerospace products, asbestos and other products. Much of his practice focuses on developing and rebutting expert medical and scientific evidence, and litigating the admissibility of expert opinion testimony.
Bert also has significant experience in antitrust cases, including a Supreme Court case that established the antitrust boundaries of private code and standard-making activities. Other litigation experience includes patent cases, managed care disputes (antitrust and contract), third-party payor claims, unfair competition, commercial contracts and false advertising.
Prior to joining Kaye Scholer, Bert was a trial attorney with the Federal Trade Commission's Bureau of Competition, where he worked on merger, monopolization and price-fixing litigations.
Bert taught legal research and writing as a Teaching Fellow at Stanford Law School. He has certificates in computer programming, statistics, and epidemiology from Harvard University and Johns Hopkins University.